406 related articles for article (PubMed ID: 8637514)
1. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
[TBL] [Abstract][Full Text] [Related]
2. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
Moreland LW; Baumgartner SW; Schiff MH; Tindall EA; Fleischmann RM; Weaver AL; Ettlinger RE; Cohen S; Koopman WJ; Mohler K; Widmer MB; Blosch CM
N Engl J Med; 1997 Jul; 337(3):141-7. PubMed ID: 9219699
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.
Mease PJ; Wei N; Fudman EJ; Kivitz AJ; Schechtman J; Trapp RG; Hobbs KF; Greenwald M; Hou A; Bookbinder SA; Graham GE; Wiesenhutter CW; Willis L; Ruderman EM; Forstot JZ; Maricic MJ; Dao KH; Pritchard CH; Fiske DN; Burch FX; Prupas HM; Anklesaria P; Heald AE
J Rheumatol; 2010 Apr; 37(4):692-703. PubMed ID: 20032102
[TBL] [Abstract][Full Text] [Related]
4. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
5. Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock of rats.
Guo Z; Wang S; Jiao Q; Xu M; Xu Z
Biomed Pharmacother; 2009 Aug; 63(7):537-42. PubMed ID: 18848768
[TBL] [Abstract][Full Text] [Related]
6. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
Mease PJ; Hobbs K; Chalmers A; El-Gabalawy H; Bookman A; Keystone E; Furst DE; Anklesaria P; Heald AE
Ann Rheum Dis; 2009 Aug; 68(8):1247-54. PubMed ID: 18678578
[TBL] [Abstract][Full Text] [Related]
7. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
Weinblatt ME; Kremer JM; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Fox RI; Jackson CG; Lange M; Burge DJ
N Engl J Med; 1999 Jan; 340(4):253-9. PubMed ID: 9920948
[TBL] [Abstract][Full Text] [Related]
8. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor receptor: Fc fusion protein in septic shock.
Whiteley MS
N Engl J Med; 1996 Nov; 335(21):1607-8; author reply 1608-9. PubMed ID: 8927111
[No Abstract] [Full Text] [Related]
10. Tumor necrosis factor receptor: Fc fusion protein in septic shock.
Glauser MP; Cohen J
N Engl J Med; 1996 Nov; 335(21):1608; author reply 1608-9. PubMed ID: 8927112
[No Abstract] [Full Text] [Related]
11. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
[TBL] [Abstract][Full Text] [Related]
13. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
[TBL] [Abstract][Full Text] [Related]
14. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
15. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans.
DeLa Cadena RA; Majluf-Cruz A; Stadnicki A; Tropea M; Reda D; Agosti JM; Colman RW; Suffredini AF
Thromb Haemost; 1998 Jul; 80(1):114-8. PubMed ID: 9684796
[TBL] [Abstract][Full Text] [Related]
16. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
18. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
Jatoi A; Dakhil SR; Nguyen PL; Sloan JA; Kugler JW; Rowland KM; Soori GS; Wender DB; Fitch TR; Novotny PJ; Loprinzi CL
Cancer; 2007 Sep; 110(6):1396-403. PubMed ID: 17674351
[TBL] [Abstract][Full Text] [Related]
19. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration.
Suffredini AF; Reda D; Banks SM; Tropea M; Agosti JM; Miller R
J Immunol; 1995 Nov; 155(10):5038-45. PubMed ID: 7594512
[TBL] [Abstract][Full Text] [Related]
20. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.
Mohler KM; Torrance DS; Smith CA; Goodwin RG; Stremler KE; Fung VP; Madani H; Widmer MB
J Immunol; 1993 Aug; 151(3):1548-61. PubMed ID: 8393046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
